Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial
Open Access
- 2 July 2025
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (7) , e70281
Abstract
HSK39297 is a novel complement factor B inhibitor, and this phase 1 trial was designed to assess its pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability in healthy Chinese subjects. This study included 46 subjects in the single ascending dose (SAD) part (50–600 mg) and 50 subjects in the multiple ascending dose (MAD) part (50–125 mg BID and 200–300 mg QD). Among them, a food effect study was conducted in the SAD 200 mg group. Adverse events (AEs) reported after the initial dose of the study drug were considered treatment‐emergent AEs (TEAEs). Blood samples were collected to measure plasma concentrations of HSK39297 at predefined time points and analyzed at a centralized laboratory. In addition, PD analysis was conducted by measuring complement alternative pathway (AP) activity and Bb concentrations. According to the results, we found single and multiple doses of HSK39297 were safe and well tolerated in all subjects. Within SAD of 50–600 mg dose range, the C max , AUC 0‐ t , and AUC 0‐∞ exhibited nonlinear PK characteristics. The high‐fat meals did not significantly affect the absorption rate and systemic exposure levels of HSK39297, and GMRs for fed versus fasting states were 108.05% (99.66%, 117.15%), 98.73% (89.34%, 109.09%), and 97.86% (84.66%, 113.11%), respectively. In MAD part, dose‐drug exposure showed a linear relationship. PD analysis indicated that oral administration of HSK39297 tablets resulted in dose‐dependent inhibition of the AP activity and Bb concentration. These findings support advancing HSK39297 into later‐phase trials for complement‐mediated glomerular diseases.Keywords
This publication has 25 references indexed in Scilit:
- Therapeutic Targeting of the Complement System: From Rare Diseases to PandemicsPharmacological Reviews, 2021
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2021
- Complement and the Kidney: An OverviewAdvances in Chronic Kidney Disease, 2020
- C3 Glomerulopathy: Pathogenesis and TreatmentAdvances in Chronic Kidney Disease, 2020
- Association of Complement and Inflammatory Biomarkers with Diabetic Nephropathy2019
- Factor B and C4b2a Autoantibodies in C3 GlomerulopathyFrontiers in Immunology, 2019
- Mechanisms of Complement-Mediated Damage in Hematological DisordersSeminars in Hematology, 2018
- Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment OptionsThe American Journal of the Medical Sciences, 2017
- C3 glomerulopathy and current dilemmasClinical and Experimental Nephrology, 2016
- The Association Between Complement Component 2/Complement Factor B Polymorphisms and Age-related Macular Degeneration: A HuGE Review and Meta-AnalysisAmerican Journal of Epidemiology, 2012